In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping The Medical Industry, April 2017

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

You may also be interested in...



Class I Recall On Penumbra Revascularization Device

A delivery wire in the stroke treatment device can break or separate during use, putting patients at risk of worsened stroke, death and other adverse events.

Earnings Winners and Losers: JNJ, MMSI, ABT, ZBH, SNN, EW, Plus Round-Up

Among the medtech companies who have released their first-quarter 2017 sales and earnings, Johnson & Johnson and Merit Medical Systems reported progress in their long-term plans to reshape their medical device businesses, while Abbott and Zimmer Biomet received some bad news in the quarter. Smith & Nephew shows signs of a turnaround, and perennial "winner" Edwards Lifesciences provided updates on some important developments in their flagship transcatheter valve business.

Deals In Depth: August 2022

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV005062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel